Sanofi's €10B sales target for Dupixent? The 'megabrand' is more than halfway there, exec says
Shortly after Sanofi CEO Paul Hudson joined the company in 2019, he laid out an ambition to invest as much as necessary to turn the Regeneron-partnered antibody drug Dupixent into a megablockbuster. Two years later, Sanofi is well on its way.
Source: fiercepharma.com